Navigation Links
Genentech and Novartis Remain Image Leaders in Oncology and Hematology
Date:6/2/2011

LIVONIA, Mich., June 2, 2011 /PRNewswire/ -- Genentech and Novartis have the best image among oncologists and hematologists, according to Market Strategies International, a market research consultancy that recently completed its 2011 MSImage study. The study evaluated more than 30 sales force, corporate equity and R&D attributes to determine which measures drive a company's image and performance in this rapidly growing marketplace.

Amgen, Sanofi-aventis and Eli Lilly/ImClone round out the top five among oncologists, and Celgene, Millennium: The Takeda Oncology Company and Amgen round out the top five for hematologists.Rank

Oncologists

Hematologists1

Genentech

Genentech2

Novartis

Novartis3

Amgen

Celgene4

Sanofi-aventis

Millennium5

Eli Lilly/ImClone

AmgenWhile Genentech maintains a slim lead across office-based and hospital-based oncologists and hematologists, Novartis remains the only other company tied with Genentech for top-tier status.  And, although Genentech slightly extended their lead across several key measures, Novartis is now ranked first by hospital oncologists in the Sales Force dimension and closed the gap on Genentech in the Product/R&D dimension.  

"Last year, Novartis joined Genentech as a top-tier company among office-based oncologists, but now the improvement is mixed. There are specific areas that Novartis needs to improve on if it hopes to claim the top spot from Genentech," said Brock Walter, vice president, Specialty Pharmaceuticals division, Market Strategies International.

Study results indicate that top performers engage in behaviors that are most important to physicians. Specifically, there is a strong correlation between a highly favorable image and behaviors such as a physician's likelihood to:

  • Recommend products to colleagues
  • Make additional time for sales reps and MSLs
  • Try new products'/>"/>

  • SOURCE Market Strategies International
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related biology technology :

    1. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
    2. Roche Intends to Commence Tender Offer to Acquire All Shares of Genentech for US$ 86.50 Per Share in Cash
    3. Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation
    4. Roche Completes Tender Offer for Genentech
    5. Agendia Supports Genentechs Citizens Petition Urging FDA to Hold In-Vitro Diagnostic Tests to One Set of Scientific and Regulatory Standards
    6. MRC Technology Enters Into an Exclusive License Agreement With Genentech
    7. PDL BioPharma Provides Third Quarter 2010 Revenue Guidance of Approximately $86 Million and Update to its Correspondence With Genentech
    8. Pfizer, Merck, Roche/Genentech, GSK, J&J, BMS and More to Speak at Contracting & Outsourcing 2010
    9. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
    10. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
    11. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2014)... North Shore Towers, a luxury co-op community based ... one of the nation’s leading combined heating and power (CHP) ... 43-year-old CHP system. The original CHP system had been maintained ... the life of the plant, GI Energy was contracted to ... recovery equipment, while maintaining continuous operation of the entire complex. ...
    (Date:7/31/2014)... -- Research and Markets has announced the ... report to their offering. ... the genetic material or genomes of an organism. It ... discovery and development of diagnostic and therapeutic solutions for ... is supported by three major product segments: Instruments, Consumables, ...
    (Date:7/31/2014)... July 31, 2014 Senomyx , ... company using proprietary taste science technologies to discover, ... food, beverage, and ingredient supply industries, today reported ... Company ended the second quarter with $33.6 million ... "During the past quarter Senomyx achieved another ...
    (Date:7/31/2014)... SHENZHEN, China , July 31, 2014 ... an Irys™System by BGI , the ... enable comprehensive exploration of human structural variation (SV) and ... interest, including those where no reference exists. In addition, ... methods for multiplexing on the Irys System, enabling significantly ...
    Breaking Biology Technology:North Shore Towers Partners with GI Energy to Install Turnkey Natural Gas-Fired Combined Heat and Power Plant 2Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 14SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 15SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 16BioNano Genomics Announces the Purchase of the Irys System by BGI 2BioNano Genomics Announces the Purchase of the Irys System by BGI 3BioNano Genomics Announces the Purchase of the Irys System by BGI 4
    ... 2011 Sigma Life Science, the innovative biological ...  SIAL), and King,s College London, today announced an ... for the identification and validation of microRNA (miRNA) ... detailed information, visit www.wherebiobegins.com/targetid . ...
    ... Reportlinker.com announces that a new market research report is available ... http://www.reportlinker.com/p0489604/Genetics-Reports-Bundle.html Report Description ... TriMark Publications reports at a15% discount off the individual reports being ... DNA Sequencing and PCR Markets. - Gene Expression ...
    ... Highlights First Quarter 2011: First ... to Alexandria Real Estate Equities, Inc.,s Common Stockholders of $1.15, ... Up 6% Compared to First Quarter 2010 FFO Per Share ... (Diluted) Attributable to Alexandria Real Estate Equities, Inc.,s Common Stockholders ...
    Cached Biology Technology:Sigma® Life Science and King's College London Co-Developing miRNA Target Identification Technology 2Sigma® Life Science and King's College London Co-Developing miRNA Target Identification Technology 3Sigma® Life Science and King's College London Co-Developing miRNA Target Identification Technology 4Reportlinker Adds Genetics Reports Bundle 2Reportlinker Adds Genetics Reports Bundle 3Reportlinker Adds Genetics Reports Bundle 4Reportlinker Adds Genetics Reports Bundle 5Reportlinker Adds Genetics Reports Bundle 6Reportlinker Adds Genetics Reports Bundle 7Reportlinker Adds Genetics Reports Bundle 8Reportlinker Adds Genetics Reports Bundle 9Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 2Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 3Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 4Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 5Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 6Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 7Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 8Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 9Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 10Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 11Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 12Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 13Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 14Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 15Alexandria Real Estate Equities, Inc. Reports First Quarter Ended March 31, 2011 Financial and Operating Results 16
    (Date:8/1/2014)... the UC Davis Center for Neuroscience and Department ... and Engineering Faculty Fellowship from the U.S. Department ... support new work on learning and memory in ... The new project aims to connect neural oscillations, ... the cortex and hippocampus, brain regions that are ...
    (Date:8/1/2014)... marine mammals have officially named a species new ... sahulensis , according to the Wildlife Conservation Society ... the newly named species is the culmination of ... historical records, physical descriptions, and genetic data of ... from the coast of West Africa to the ...
    (Date:8/1/2014)... in stem cell research will provide enormous opportunities ... stem cells could replicate any other cells in ... disease, repairing damaged spinal cords, treating kidney, liver ... The potential for profit is staggering. Prof. Jinhui ... this field of research still faces myriad biological, ...
    Breaking Biology News(10 mins):Scientists name new species of cetacean: The Australian humpback dolphin 2Scientists name new species of cetacean: The Australian humpback dolphin 3
    ... (PHILADELPHIA) Scientists at Jefferson Medical College have received ... funded by the National Heart, Lung and Blood Institute ... of platelet gene expression. The study aims to find ... strategies and develop better predictors of cardiovascular disease. ...
    ... Researchers have tracked a cell-to-cell signaling pathway that designates ... embryonic mice. The scientists succeeded in activating this signal ... inner ear. Patches of sensory structures began growing in ... structures contained tufted cells, called hair cells, which respond ...
    ... New ground broken by Michigan State University biochemists ... temperatures and could lead to discoveries related to ... "This brings together two classic problems in ... biochemistry and molecular biology. "One is that plants ...
    Cached Biology News:Jefferson receives $3 million NIH grant to study molecular and genetic mechanisms in platelets 2Tuning into cell signals that tell where sensory organs will form inside the ear 2Tuning into cell signals that tell where sensory organs will form inside the ear 3Researchers discover novel mechanism protecting plants against freezing 2
    Human FGF R2 (alpha isoforms) MAb (Clone 98706)...
    dithiothreitol, sulfhydryl reducing agent, C4H10O2S2; MW: 154.24, 97% pure (minimum), CAS No: 27565-41-9, store at -20 C ...
    ... the simple, phenol-free extraction of genomic DNA ... proteinase K digestion.Each kit is designed to ... of up to 25 mg of hard ... and Amplification of Genomic DNA, Nucleon DNA ...
    Human LT beta R/TNFRSF3 Phycoerythrin MAb (Clone 71319)...
    Biology Products: